Buprenorphine Hydrochloride

CHEMBL2368861 Phase 4 Aprobado Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

504.1 g/mol

LogP

—

Phase

4

The hydrochloride salt of buprenorphine, used to treat opioid dependence and chronic pain. It is available in sublingual, buccal, transdermal, and injectable formulations. Its partial agonist activity at mu-opioid receptors provides pain relief and reduces withdrawal while limiting abuse potential.

Peso molecular

504,1000 g/mol

TPSA

62,20 Å²

Áreas terapéuticas

Artritis reumatoide Cáncer colorrectal Cáncer de mama Cáncer de ovario Cáncer de páncreas Cáncer de próstata Cáncer de pulmón de células no pequeñas Cáncer de tiroides Cáncer de vejiga Dolor crónico Enfermedad cardiovascular Esquizofrenia Hepatitis C Insomnio Manejo del dolor Obesidad Psiquiatría Trastorno de ansiedad generalizada Trastorno depresivo mayor VIH/sida

Mecanismo de acción

Binds to mu (μ), kappa (κ), and/or delta (δ) opioid receptors in the central and peripheral nervous system, mimicking endogenous endorphins. Activation of these G-protein-coupled receptors inhibits pain signal transmission and modulates the emotional response to pain.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mecanismo

Binds to mu (μ), kappa (κ), and/or delta (δ) opioid receptors in the central and peripheral nervous system, mimicking endogenous endorphins. Activation of these G-protein-coupled receptors inhibits pain signal transmission …

Estructura 2D

SVG PNG

Cite this structure

Embed this structure

SMILES

CO[C@@]12CC[C@@]3(C[C@@H]1[C@](C)(O)C(C)(C)C)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5.Cl

InChI

InChI=1S/C29H41NO4.ClH/c1-25(2,3)26(4,32)20-15-27-10-11-29(20,33-5)24-28(27)12-13-30(16-17-6-7-17)21(27)14-18-8-9-19(31)23(34-24)22(18)28;/h8-9,17,20-21,24,31-32H,6-7,10-16H2,1-5H3;1H/t20-,21-,24-,26+,27-,28+,29+;/m1./s1

Molecular Formula

C29H42ClNO4

HBD / HBA

3 / 5

Enlaces Rotables

5

Átomos Pesados

35

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Preguntas frecuentes

The hydrochloride salt of buprenorphine, used to treat opioid dependence and chronic pain. It is available in sublingual, buccal, transdermal, and injectable formulations. Its partial agonist activity at mu-opioid receptors provides pain relief and reduces withdrawal while limiting abuse potential.

Binds to mu (μ), kappa (κ), and/or delta (δ) opioid receptors in the central and peripheral nervous system, mimicking endogenous endorphins. Activation of these G-protein-coupled receptors inhibits pain signal transmission and modulates the emotional response to pain.

Yes, Buprenorphine Hydrochloride is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL2368861. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 3033050. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

PillFYI

¿Busca información accesible para el paciente?

Buprenorphine Hydrochloride en PillFYI

Estructura

Datos Rápidos

Fórmula: C29H42ClNO4
Sinónimos: 5

Enlaces externos

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Aviso médico

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.